News | April 6, 2023

Greenphire Appoints Steve Geffon As Chief Commercial Officer

Source: Greenphire

King of Prussia, PA (April 3, 2023) – Greenphire, the global leader in clinical trial patient engagement and financial lifecycle management, has appointed Steve Geffon as its new Chief Commercial Officer (CCO). In this executive committee role, Geffon is responsible for leading and expanding upon Greenphire’s proven go-to-market strategy, aligning client objectives with a growing suite of technology solutions to assist clinical researchers in getting treatments and cures to market faster.

Amidst a backdrop of dramatic growth and increasing complexity in the research industry, sites, sponsors and CROs are unified in their desire to improve the patient experience and create efficiencies across the clinical trial lifecycle. In Greenphire’s latest clinical trial market research survey, sponsors and CROs overwhelmingly agreed that new technology for study operations are what makes them optimistic about working in this field today. Greenphire has been a consistent trailblazer of eClinical technology, successfully innovating new solutions leveraged by the most respected academics, sponsors and CROs to drive access and insight from study start up through closeout.

“We are thrilled to have Steve join the Greenphire team as our Chief Commercial Officer,” said Jim Murphy, CEO of Greenphire. “His deep clinical trial knowledge, client-centered approach and broad experience are invaluable at this pivotal time of acceleration. We are confident that Steve is the perfect fit to provide commercial leadership as we broaden our suite of solutions to solve a growing array of challenges in clinical research.”

Geffon joined Greenphire most recently from Science 37, where he served as Chief Commercial Officer and was responsible for leading commercial operations and developing strategic partnerships. Prior to this, he led sales and marketing as Chief Commercial Officer at Medrio, a leading SaaS data capture platform. Additionally, Geffon was also instrumental in ERT’s success, leading sales efforts through a period of unprecedented growth and profitability for nearly 15 years.

Whereas some eClinical companies have struggled in recent years, Greenphire established itself as the market leader by assisting clients on their mission to connect disparate processes, empower study teams and increase revenue. The company’s unique fintech and data regulatory expertise and coupled with on-the-ground global footprint and capabilities is a powerful value proposition which has led to unprecedented growth and untapped opportunity for the future.

“I am delighted to join the team at Greenphire and be part of its shared mission to transform how the business of research is conducted. My background in developing successful go-to-market strategies and building effective teams will be beneficial as the company continues to provide cutting-edge software solutions for clinical trials,” said Geffon.

Watch this video to see how Greenphire is enabling Smarter Trials from Beginning to End. To learn more about the company and its solutions, visit:

About Greenphire

Greenphire’s suite of best-in-class technology solutions enables clients to prioritize the patient journey, so treatments and cures are delivered to those who need them faster.

Committed to modernizing and integrating each step in the participant journey and the overall clinical trial lifecycle, Greenphire has established a mobile-enabled technology platform which offers a personalized and empowering end-to-end participant experience from trial identification (patient registry) through participation. ClinCard® and ConneX® remove financial and logistical barriers, simplifying the delivery of global patient convenience initiatives and improving recruitment and retention. Greenphire’s EnvisiXTM and eClinicalGPS® transform the budgeting and site payment process, resulting in expedited study start up and improved site sustainability.

The choice of industry leaders worldwide, Greenphire provides better performance and better data, resulting in better trials. Learn more at

Source: Greenphire